AI-generated analysis. Always verify with the original filing.
NeOnc Technologies Holdings, Inc. reported Q4 and full-year 2025 financial results with a $62.1 million net loss, alongside clinical progress in NEO212 Phase 1 completion and NEO100 Phase 2a full enrollment.
Event Type
Disclosure
Mandatory
Variant
8-K
and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”
. | Regulation FD Disclosure. | |---|---| The information under Item 2.02, above, is incorporated herein by reference. The information reported under Items 2.02
. | Financial Statements and Exhibits. | |---|---| (d) Exhibits | Exhibit No. | | Description | |---|---|---| | 99.1 | | Press Release, dated April 1, 2026 | |
| Metric | Value | Basis |
|---|---|---|
| G&A expenses | $4.8K | |
| R&D expenses | $3.6K | |
| Net loss | $62.10 | |
| Diluted EPS | $-3.20 |
Amir Heshmatpour
lead clinical and corporate development
David Choi
oversee accounting, financial reporting, internal controls, corporate governance